华森制药
(002907)
| 流通市值：50.84亿 | | | 总市值：68.74亿 |
| 流通股本：3.09亿 | | | 总股本：4.18亿 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 238,944,153.42 | 774,819,866.89 | 614,223,361.57 | 417,852,265.17 |
| 营业收入 | 238,944,153.42 | 774,819,866.89 | 614,223,361.57 | 417,852,265.17 |
| 二、营业总成本 | 189,330,193.11 | 699,830,140.66 | 534,304,062.41 | 361,848,490.3 |
| 营业成本 | 97,438,325.28 | 331,050,582.43 | 259,861,828.77 | 175,944,194.61 |
| 税金及附加 | 2,554,236.96 | 12,105,852.91 | 7,833,077.47 | 6,051,458.26 |
| 销售费用 | 68,872,834.62 | 250,533,803.89 | 196,181,589.06 | 133,698,419.66 |
| 管理费用 | 12,696,210.99 | 57,827,627.93 | 41,032,795.9 | 27,768,062.4 |
| 研发费用 | 12,304,890.58 | 59,129,476.89 | 38,987,662.38 | 25,843,637.72 |
| 财务费用 | -4,536,305.32 | -10,817,203.39 | -9,592,891.17 | -7,457,282.35 |
| 其中:利息费用 | 1,507.67 | -518,913.86 | -344,416.8 | 4,338.7 |
| 其中:利息收入 | 4,603,017.85 | 10,321,090.55 | 9,333,877.67 | 7,513,021.29 |
| 加:公允价值变动收益 | 471,129.47 | 7,518,348.83 | 437,865.06 | 90,100.79 |
| 加:投资收益 | -811,330.04 | -6,140,731.36 | -3,438,914.87 | -2,836,418.72 |
| 资产减值损失(新) | -86,852.9 | -1,859,620.57 | -1,068,293.84 | -397,153.79 |
| 信用减值损失(新) | -2,014,007.51 | -1,635,836.57 | -3,861,266.09 | -2,198,119.49 |
| 其他收益 | 2,348,546.56 | 20,928,702.94 | 17,066,173.96 | 6,976,770.02 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 49,521,445.89 | 93,800,589.5 | 89,054,863.38 | 57,638,953.68 |
| 加:营业外收入 | 24,571.01 | 208,049.11 | 202,728.95 | 75,142.94 |
| 减:营业外支出 | 244,679.28 | 566,699.92 | 584,723.52 | 513,852.35 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 49,301,337.62 | 93,441,938.69 | 88,672,868.81 | 57,200,244.27 |
| 减:所得税费用 | 8,946,125.24 | 16,711,713.57 | 14,096,033.18 | 9,985,348.15 |
| 六、净利润 | 40,355,212.38 | 76,730,225.12 | 74,576,835.63 | 47,214,896.12 |
| 持续经营净利润 | 40,355,212.38 | 76,730,225.12 | 74,576,835.63 | 47,214,896.12 |
| 归属于母公司股东的净利润 | 40,355,212.38 | 76,730,225.12 | 74,576,835.63 | 47,214,896.12 |
| (一)基本每股收益 | 0.1 | 0.18 | 0.18 | 0.11 |
| (二)稀释每股收益 | 0.1 | 0.18 | 0.18 | 0.11 |
| 八、其他综合收益 | -6,070.86 | 244,061.74 | -173,845.46 | 101,866.35 |
| 归属于母公司股东的其他综合收益 | -6,070.86 | 244,061.74 | -173,845.46 | 101,866.35 |
| 九、综合收益总额 | 40,349,141.52 | 76,974,286.86 | 74,402,990.17 | 47,316,762.47 |
| 归属于母公司股东的综合收益总额 | 40,349,141.52 | 76,974,286.86 | 74,402,990.17 | 47,316,762.47 |
| 公告日期 | 2025-04-25 | 2025-04-25 | 2024-10-29 | 2024-08-22 |
| 审计意见(境内) | | 标准无保留意见 | | |